Drug Type CAR-NK |
Synonyms CYT 150, CYT-150 |
Target |
Mechanism GPC3 modulators(Glypican-3 modulators), Natural killer cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Cytovia Therapeutics, Inc.Startup |
Active Organization Cytovia Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Preclinical | US | Cytovia Therapeutics, Inc.Startup | 12 Apr 2022 |
Hematologic Neoplasms | Preclinical | US | Cytovia Therapeutics, Inc.Startup | 10 Nov 2020 |